{
  "name": "Neuroimmunology",
  "slug": "neuroimmunology",
  "icon": "üõ°Ô∏è",
  "color": "bg-sky-100 text-sky-800 border-sky-200",
  "toc": [
    {
      "level": 1,
      "text": "Pediatric White Matter Changes",
      "id": "pediatric-white-matter-changes"
    },
    {
      "level": 1,
      "text": "Autoimmune Encephalitis",
      "id": "autoimmune-encephalitis"
    },
    {
      "level": 3,
      "text": "Anti-NMDA Encephalitis",
      "id": "anti-nmda-encephalitis"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis"
    },
    {
      "level": 1,
      "text": "Transverse myelitis",
      "id": "transverse-myelitis"
    },
    {
      "level": 3,
      "text": "Epidemiology:",
      "id": "epidemiology"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-2"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-2"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-2"
    },
    {
      "level": 1,
      "text": "Acute Disseminated Encephalomyelitis (ADEM)",
      "id": "acute-disseminated-encephalomyelitis-adem"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation-2"
    },
    {
      "level": 3,
      "text": "Diagnostic Criteria (IPMSSG 2007)",
      "id": "diagnostic-criteria-ipmssg-2007"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-3"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-3"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-3"
    },
    {
      "level": 1,
      "text": "Inflammatory Disorders Associated with OCBs",
      "id": "inflammatory-disorders-associated-with-ocbs"
    },
    {
      "level": 1,
      "text": "Pediatric Multiple Sclerosis",
      "id": "pediatric-multiple-sclerosis"
    },
    {
      "level": 3,
      "text": "Diagnosis:",
      "id": "diagnosis"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-4"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-4"
    },
    {
      "level": 1,
      "text": "Optic Neuritis",
      "id": "optic-neuritis"
    },
    {
      "level": 3,
      "text": "Epidemiology:",
      "id": "epidemiology-2"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation-3"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-5"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-5"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-4"
    },
    {
      "level": 1,
      "text": "Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "id": "neuromyelitis-optica-spectrum-disorder-nmosd"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-6"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-6"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-5"
    },
    {
      "level": 1,
      "text": "MOG Antibody Disease (MOGAD)",
      "id": "mog-antibody-disease-mogad"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation-4"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-7"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-7"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-6"
    },
    {
      "level": 1,
      "text": "Facial nerve (cranial nerve VII) palsy",
      "id": "facial-nerve-cranial-nerve-vii-palsy"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation-5"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-7"
    },
    {
      "level": 1,
      "text": "Post-viral cerebellar ataxia / cerebellitis",
      "id": "post-viral-cerebellar-ataxia-cerebellitis"
    },
    {
      "level": 3,
      "text": "Epidemiology:",
      "id": "epidemiology-3"
    },
    {
      "level": 3,
      "text": "Clinical Presentation:",
      "id": "clinical-presentation-6"
    },
    {
      "level": 3,
      "text": "Evaluation:",
      "id": "evaluation-8"
    },
    {
      "level": 3,
      "text": "Treatment:",
      "id": "treatment-8"
    },
    {
      "level": 3,
      "text": "Prognosis:",
      "id": "prognosis-8"
    }
  ],
  "html": "<h1 id=\"pediatric-white-matter-changes\">Pediatric White Matter Changes</h1><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pediatric White Matter Changes </strong>(things to think about ‚Äì although some of these are exceptionally rare and do not come up often)</p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Endocrine</strong></p></td><td><p>Thyroid disorder, diabetes mellitus</p></td></tr><tr><td><p><strong>Inflammatory</strong></p></td><td><p>SLE, neurosarcoidosis, Sjogrens, APLAS, Behcet disease, Primary angiitis of the CNS </p></td></tr><tr><td><p><strong>Mitochondrial</strong></p></td><td><p>MERRF, MELAS, LHON, Leigh, Kearns-Sayre</p></td></tr><tr><td><p><strong>Leukodystrophy</strong></p></td><td><p>Metachromatic leukodystrophy, adrenoleukodystrophy, Krabbe, Pelizaeus-Merzbacher, Refsum, Vanishing White Matter, Leukoencephalopathy with brainstem and SC involvement &amp; elevated lactate, Wilsons, Fabry, Alexander</p></td></tr><tr><td><p><strong>Genetic/Metabolic</strong></p></td><td><p>Inborn errors of metabolism, aminoacidurias</p></td></tr><tr><td><p><strong>Infectious</strong></p></td><td><p>Neuroborreliosis (Lyme), HSV encephalitis, HIV, Neurocysticercosis, post-streptococcal infection, abscess, neurosyphilis, PML, Whipple‚Äôs disease</p></td></tr><tr><td><p><strong>Vascular</strong></p></td><td><p>CADASIL, Moyamoya, carotid dissection</p></td></tr><tr><td><p><strong>Demyelinating</strong></p></td><td><p>CIS, ADEM, ON, TM, NMO, ANE, MOG</p></td></tr><tr><td><p><strong>Nutritional</strong></p></td><td><p>B12, E or folate deficiency, celiac</p></td></tr><tr><td><p><strong>Neoplastic</strong></p></td><td><p>Lymphoma, astrocytoma, medulloblastoma, metastases</p></td></tr><tr><td><p><strong>Toxic </strong></p></td><td><p>Radiation, chemo (MTX, cyclosporine, cytosine-arabinoside), extrapontine myelinolysis</p></td></tr><tr><td><p><strong>Other</strong></p></td><td><p>Langerhans cell histiocytosis, hemophagocytic lymphohistiocytosis</p></td></tr></tbody></table></div><p><strong>&nbsp;</strong></p><p><strong>Work-up of white matter changes: </strong>Start with Tier 1 if the lesion looks odd or is very prominent (higher risk lesion ‚Äì periventricular or juxtacortical) and continue to other tiers if symptomatic, severe, or progressing over time. Consider jumping to higher tiers if risk factors are present (presence of DD, presence of specific exposures, regression, etc)</p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>CSF</strong></p></td><td><p><strong>Serum</strong></p></td><td><p><strong>Imaging</strong></p></td></tr><tr><td><p><strong>Tier 1</strong></p></td><td><p>OCB, IgG Index, cell count, protein, glucose; +/- HSV</p></td><td><p>CBC, ESR, CRP, NMO Ab, MOG Ab, ANA panel (including SSA, SSB, etc), TSH, B12, Vitamin D 25-OH level</p></td><td><p>Brain and C spine with/ without gadolinium </p><p>Other: ophtho exam prn</p></td></tr><tr><td><p><strong>Tier 2</strong></p></td><td><p>EV, Lyme (if travel to East coast), cytology, bacterial, fungal, viral cultures, NMO Ab (if suspicion is high)</p></td><td><p>ACE, HIV, RPR/FTA, autoimmune encephalopathy Ab panel</p></td><td><p>Repeat brain MRI (usually in a few months if high risk lesion, and if patient is stable), cervical/thoracic spinal cord with/without gadolinium, CT chest (sarcoid)</p></td></tr><tr><td><p><strong>Tier 3</strong></p></td><td><p>HTLV1, Measles ab (SSPE), lactate, pyruvate, autoimmune encephalopathy Ab panel</p></td><td><p>SAA, mitochondrial panel, WBC enzymes, VLCFA, acylcarnitine profile, lysosomal enzymes</p></td><td><p>MRS, MRA, PET scan</p><p>Other: </p><p>Urine OA</p><p>Brain biopsy</p></td></tr></tbody></table></div><p>Reference: Hahn, Jin S. et al. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology 2007; 68: S13-S20.</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"autoimmune-encephalitis\">Autoimmune Encephalitis</h1><p>&nbsp;</p><p><strong>Useful reference: ‚ÄúLikely Immune-Mediated Epilepsy/Encephalitis Syndromes‚Äù (LIMES) </strong><br>&nbsp;</p><h3 id=\"anti-nmda-encephalitis\"><strong>Anti-NMDA Encephalitis</strong></h3><p><strong>Epidemiology: </strong>40% of all patients are younger than 18 yr, uncommonly associated with teratoma in young children.</p><p><strong>&nbsp;</strong></p><p><strong>Clinical:</strong></p><ul><li><ul><li>Psychiatric: hallucinations, paranoia, temper tantrums, episodic agitation </li><li>Movement d/o: chorea, oromotor dyskinesias </li><li>Speech reduction/mutism </li><li>Seizures </li><li>Autonomic instability ‚Äì ‚ÜëHR, hypertension, hypoventilation, enuresis </li><li>Sleep disturbance ‚Äì wake frequently throughout the night ‚Äì insomnia is seen often</li></ul></li></ul><h3 id=\"evaluation\"><strong>Evaluation:</strong></h3><ul><li><ul><li>MRI Brain with and without contrast</li><li>LP with cell count, protein, glucose, OCBs, CSF peds autoimmune CNS disorders panel </li><li>Serum studies: consider CSF peds autoimmune CNS disorders panel and alternative causes of encephalopathy, movement d/o, etc.</li><li>EEG if concerned for seizure.  Some interictal EEG patterns are thought to support the diagnosis <em>(new onset epileptic encephalopathy ‚Äì slowing and multifocal discharges in previously normal child, extreme delta brush - more in adults)</em>.</li><li>Abdominal/pelvic MRI/US or testicular US to r/o teratoma.</li></ul></li></ul><p>&nbsp;</p><p><strong>Diagnostic Criteria (Graus 2016)</strong></p><p><strong>Probable </strong>anti-NMDA receptor encephalitis (Diagnosis can be made when <strong>all three</strong> of the following criteria have been met):</p><p>&nbsp;</p><p>1.) Rapid onset (less than 3 months) of <strong>at least four</strong> of the six following major groups of symptoms:</p><ul><li><ul><li>Abnormal (psychiatric) behavior or cognitive dysfunction</li><li>Speech dysfunction (pressured speech, mutism, verbal reduction</li><li>Seizures</li><li>Movement disorder (rigidity, posturing, dyskinesias)</li><li>Decreased LOC</li><li>Autonomic dysfunction or central hypoventilation</li></ul></li></ul><p>&nbsp;</p><p>2.) <strong>At least one</strong> of the following laboratory results</p><ul><li><ul><li>Abnormal EEG (focal or diffuse slowing, disorganized activity, epileptiform discharges, or extreme delta brush)</li><li>CSF with pleocytosis OR oligoclonal bands</li></ul></li></ul><p>&nbsp;</p><p>3.) Reasonable exclusion of other causes</p><p>&nbsp;</p><p>**Can have any of <strong>three </strong>of the above in the presence of a teratoma and also make the diagnosis.</p><p>&nbsp;</p><p><strong>Definite </strong>anti-NMDA receptor encephalitis =<strong> any one or more</strong> of the six major groups of symptoms + antibodies to NMDA-R.</p><p>&nbsp;</p><p>&nbsp;</p><h3 id=\"treatment\"><strong>Treatment:</strong></h3><ul><li><ul><li>Acute: Typically includes high dose methylprednisolone followed by IVIG or PLEX (3-5 days).  Refractory patients have been treated with Cyclophosphamide.</li><li>Maintenance: Rituximab treatment typically q week x4 doses (started shortly after IVIG/PLEX) then every 6 months for two years</li><li>Symptomatic: ASM if seizures, usually PT, OT, ST, maybe Rehab. Good to have School specialist +/- Neuropsych involved. Psychiatry consult is usually needed for agitation, hallucinations, catatonia, or sleep. (Patients are typically very sensitive to antipsychotics, higher risk of EPS).</li></ul></li></ul><p>&nbsp;</p><h3 id=\"prognosis\"><strong>Prognosis:</strong></h3><ul><li><ul><li>80% have substantial to full recovery.<ul><li>Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score (including intensive care unit admission, treatment delay &gt;4 weeks, lack of clinical improvement within 4 weeks, abnormal MRI, and CSF white blood cell count &gt;20 cells/ŒºL) is useful for prognostication</li><li>Seizures usually remit after the encephalitis and other symptoms get under better control</li><li>Up to 20% recurrence rate in children</li><li>If treatment refractory or relapsing, think about further evaluation for teratoma (including extra-pelvic)</li></ul></li></ul></li></ul><p>&nbsp;</p><p><strong>References: </strong></p><ul><li><ul><li>Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology. 2019 Jan 15;92(3)</li><li>Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.&nbsp;<em>Lancet Neurol</em>. 2011;10(1):63-74.</li><li>Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. <em>Lancet Neurol</em>. 2016 Apr;15(4):391-404.</li></ul></li></ul><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"transverse-myelitis\">Transverse myelitis</h1><p>&nbsp;</p><h3 id=\"epidemiology\"><strong>Epidemiology:</strong></h3><ul><li>Para-infectious 47% </li><li>Post-vaccination 28%</li><li>Age: (two peaks) below age 3, and between 5 and 17 yo</li></ul><p>&nbsp;</p><h3 id=\"clinical-presentation\"><strong>Clinical Presentation:</strong></h3><ul><li>Presentation with sensory, motor, or autonomic dysfunction (bowel, bladder, etc) attributable to the spinal cord, sensory level</li><li>Severe impairment during illness (89% non-ambulatory; bladder catheterization in 82%)</li><li>Progression to nadir between 4 hours and 21 days of symptom onset</li></ul><p>&nbsp;</p><p><strong>Differential: </strong></p><ul><li>NMO, MOG, rheumatologic (see MS work-up below), hypercoagulable state/spinal cord infarct (see hypercoag work-up in stroke section). More rare: HIV, Leigh, ANCA vasculitidies</li></ul><p>&nbsp;&nbsp;</p><h3 id=\"evaluation-2\"><strong>Evaluation:</strong></h3><ul><li>MRI brain and C/T spine with and without contrast</li><li>CSF studies: <ul><li>basic studies + OCBs --- viral studies to consider (HSV, EBV, enterovirus, or MEP). Lyme if travel to East coast.</li><li>Pleocytosis in 50%</li><li>Elevated protein in 48%</li><li>OCBs &lt;5% </li></ul></li><li>Serum NMO antibody</li><li>Serum anti-MOG antibody</li><li><strong>Other lab considerations: </strong><ul><li>HIV, ANA panel, sarcoid, IgG index, TSH, B12, Vit D. </li></ul></li></ul><p>&nbsp;</p><h3 id=\"treatment-2\"><strong>Treatment:</strong></h3><ul><li>IV methylpred 30mg/kg (max 1g) x 5 days, consider PLEX for severe cases<ul><li>Oral steroid taper if concern for NMO or MOGAD and labs are still pending</li><li>Refractory ‚Äì Consider ritux or cyclophosphamide</li></ul></li></ul><p>&nbsp;</p><h3 id=\"prognosis-2\"><strong>Prognosis:</strong></h3><ul><li>Mortality / Morbidity<ul><li>2 of 47 died</li><li>Complete sphincter control in 46%</li><li>Complete locomotion in 67% </li><li>Better functional outcome if: older age, shorter time to dx, lower/fewer levels, no acute T1 hyperintensity, no pleocytosis</li></ul></li></ul><p>Recurrence</p><ul><li>Risk of MS: one of 47 patients with a mean follow up of 8 years</li><li>90% monophasic; the 10% that were not usually had underlying diagnosis of SLE, NMO, ADEM</li></ul><p>&nbsp;</p><p>Reference: Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68:1474‚Äì1480</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"acute-disseminated-encephalomyelitis-adem\">Acute Disseminated Encephalomyelitis (ADEM)</h1><p>&nbsp;</p><h3 id=\"clinical-presentation-2\"><strong>Clinical Presentation:</strong></h3><ul><li>Age: Several months to 16 years, although usually &lt; 11 y</li><li>Preceding events<ul><li>Non-specific URI, GI illness, or other febrile illness ‚Äì 53%</li><li>Immunization (measles/pertussis) ‚Äì 12%</li><li>No prodrome ‚Äì 26%</li></ul></li><li>Presenting features<ul><li>Encephalopathy (part of diagnostic criteria) </li><li>Long tract signs, ataxia, cranial nerve palsy, seizures, meningeal reaction, optic neuritis, and extrapyramidal signs may be seen</li></ul></li></ul><p>&nbsp;</p><p>&nbsp;</p><h3 id=\"diagnostic-criteria-ipmssg-2007\"><strong>Diagnostic Criteria (IPMSSG 2007)</strong></h3><p>Monophasic ADEM</p><p>Clinical Criteria</p><ul><li>First clinical event with presumed inflammatory of demyelinating cause with acute or subacute onset that affects multifocal areas</li><li>No history or concern for prior demyelinating event</li><li>No other etiologies can explain the event</li><li>Must be polysymptomatic and must include encephalopathy</li><li>Behavioral change (confusion or excessive irritability)</li><li>Alteration in consciousness (lethargy, coma)</li><li>Within the next 3 months, new or fluctuating symptoms, signs, or MRI occur within 3 months of the inciting ADEM</li><li>Event should be followed by improvement, either clinically or on MRI, although deficits may remain</li></ul><p>Neuroimaging</p><ul><li>Focal or multifocal lesions, predominantly involving the white matter, without radiologic evidence of previous destructive WM changes</li><li>Brain MRI reveals large (1-2cm) multifocal lesions involving the supra or infratentorial WM; gray matter, especially BG and thalamus is frequently involved</li><li>Rarely may show a single large lesion</li><li>Spinal cord may show confluent intramedullary lesions with variable enhancement</li></ul><p>&nbsp;</p><h3 id=\"evaluation-3\"><strong>Evaluation:</strong></h3><ul><li>Serum: Anti-MOG, anti-NMO<ul><li>40% with anti-MOG antibodies; persistence at 6 months correlated with recurrence</li><li>Recurrent ADEM or recurrent ON after ADEM may be a variant of MOG</li></ul></li><li>MRI Brain with and without contrast<ul><li>Multifocal bilateral, asymmetric FLAIR hyperintensities in cerebral WM, basal ganglia, brainstem, cerebellum, thalami, or spinal cord</li><li>Enhancement in 30%, open ring</li></ul></li><li>LP with cell count, diff, protein, glucose, OCBs, MEP<ul><li>Pleocytosis or elevated protein in 28%</li><li>OCBs can be positive up to 25% in cases</li><li>Consider CSF anti-MOG if other signs concerning for MOGAD, but serum is negative</li></ul></li></ul><p>&nbsp;</p><h3 id=\"treatment-3\"><strong>Treatment:</strong></h3><ul><li>Steroids: IV methylprednisolone 30 mg/kg/day (max 1g) qday for 3-5 days.  If concern for NMO or MOG and labs are still pending, follow with  prednisone of 1 mg/kg/day x 10 days, then slow 4-6 week taper.  No taper if suspected CIS (MS spectrum). </li></ul><p>&nbsp;</p><h3 id=\"prognosis-3\"><strong>Prognosis:</strong></h3><ul><li>Generally excellent<ul><li>Hemiparesis (mild to severe) ‚Äì 8%</li><li>Partial epilepsy ‚Äì 6%</li><li>‚ÄúMental Handicap‚Äù ‚Äì 4%</li></ul></li><li>10% of patients had relapse within 3 years +/- 2 years. All of these had negative OCBs. Unclear if ‚Äúrecurrent or multiphasic ADEM‚Äù is actually anti-MOG disease</li></ul><p><strong>&nbsp;</strong></p><p><strong>Reference: </strong></p><p>Tenembaum et al. 2002. Neurology. 59:1224-1231.</p><p>Tenembaum et al. 2007. Neurology. 68 (Suppl 2): S23-S3</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"inflammatory-disorders-associated-with-ocbs\">Inflammatory Disorders Associated with OCBs</h1><p>&nbsp;</p><p>&nbsp;</p><ul><li><ul><li>MS ‚Äì 98% (Generally is &gt;=4 OCBs)</li><li>NMO ‚Äì 18%</li><li>MOG ‚Äì 11%</li><li>Neuro-SLE ‚Äì 50%</li><li>Neuro-Behcet‚Äôs ‚Äì 20%</li><li>Neurosarcoidosis ‚Äì 5-33% </li><li>Other causes of +OCBs<ul><li>Neuro-infections - Neurosyphilis, Neuro-HIV, Neuro-lyme, SSPE</li><li>Neuro-genetic/metabolic - ataxia-telangiectasia, adrenoleukodystrophy, cerebral folate deficiency</li></ul></li><li>Rule of thumb for intermediate findings: 2 OCBs is not clearly inflammatory (higher false positive for non-inflammatory things), 3 OCBs is likely incidental unless the clinical symptoms fit a disease associated with OCBs, and if 4 OCBs, would consider if immunotherapy trial is warranted</li></ul></li></ul><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"pediatric-multiple-sclerosis\">Pediatric Multiple Sclerosis</h1><p>&nbsp;</p><h3 id=\"diagnosis\"><strong>Diagnosis: </strong></h3><p>2017 Revised McDonald Criteria</p><ul><li><strong>To diagnose MS, you need BOTH dissemination in time AND dissemination in space</strong></li><li><strong>Also reasonable exclusion of other causes ‚Äúno better explanation for the clinical presentation‚Äù</strong></li></ul><p><strong>&nbsp;</strong></p><p><strong>Dissemination in Time Criteria</strong></p><p>2 or more clinical attacks OR </p><p>1 clinical attack PLUS one of the following</p><ul><li>Additional clinical attack</li><li>MRI showing simultaneous contrast enhancing and non-contrast enhancing lesions</li><li>Follow-up MRI showing new T2 lesion or new contrast enhancement</li><li>Presence of oligoclonal bands</li></ul><p>&nbsp;</p><p><strong>Dissemination in Space Criteria</strong></p><p>2 or more lesions with objective clinical evidence OR</p><p>One lesion with objective clinical evidence PLUS</p><p>One or more T2 hyperintense lesions characteristic of MS in two or more of four areas of the CNS</p><ul><li>Periventricular</li><li>Cortical or juxtacortical</li><li>Infratentorial </li><li>Spinal cord</li></ul><p>&nbsp;</p><h3 id=\"evaluation-4\"><strong>Evaluation:</strong></h3><ul><li>MRI brain with and without contrast, consider spinal imaging if myelopathic symptoms</li><li>Mimics: LP with cell count/diff, IgG Index, OCBs (serum and CSF drawn at same time in CHCO lab), ANA profile, ACE (if concern for sarcoid), HIV Ab/Ag, NMO, MOG</li><li>Vitamin D</li><li>For DMARD initiation labs (Ritux or Gilenya): preg test (post-pubertal females), CBC, CMP, JCV Ab (send out to Quest), TB QuantiFERON PLUS</li><li>For Ritux initiation: Hep B core +surface ab/Ag, Hep C total antibodies, immunoglobulin panel (IgG, IgM, IgA), anti-CD20 monitoring panel</li><li>For Gilenya: ophtho eval with OCTs, VZV serologies (vaccinate prior to starting), consider PFTs (asthma)</li></ul><p>&nbsp;</p><h3 id=\"treatment-4\"><strong>Treatment:</strong></h3><ul><li>Acute Flares:</li><li>Ensure not a pseudo flare: Look-for infectious causes, stress-related triggers (symptoms usually the same as prior flares, and lasting &lt;24 hours)<ul><li>IV methylprednisolone 30mg/kg/day (max 1g) q24 hours for 3-5 days; no taper<ul><li>Can sometimes be arranged through the infusion center instead of admission, or may use very high dose oral pred (up to 1250mg/day, not for first dose or severe presentation, sometimes difficult to do ‚Äì 25 pills)</li></ul></li><li>GI prophylaxis</li></ul></li><li>Chronic/Disease Modifying Therapies (DMTs)</li><li>Vit D supplementation (goal levels 40-80)</li><li>Many different DMTs available, the ones given here are the more commonly used based on safety/efficacy</li><li>Many approaches to DMTs contingent on route of admin, insurance, efficacy, level of initial aggressiveness of treatment, and risk factors</li><li>One suggested approach:<ul><li>If wanting an oral med, could discuss Fingolimod (Gilenya)</li><li>If JCV positive or treatment failure with first line, consider ritux or ocrelizumab</li><li>If JCV negative, could also discuss Tysabri (infusible)</li></ul></li></ul><p>&nbsp;</p><p>&nbsp;</p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Drug</strong></p></td><td><p><strong>MOA/Efficacy</strong></p></td><td><p><strong>Dose (adult)</strong></p></td><td><p><strong>Side Effects</strong></p></td><td><p><strong>Monitoring</strong></p></td></tr><tr><td><p><strong>Natalizumab (Tysabri) </strong></p><p>&nbsp;</p></td><td><p>Monoclonal antibody that binds to alpha4-integrin and inhibits migration of leukocytes from blood to CNS and preventing costimulatory activating signals, reducing plaque formation </p><p>ARR reduced by 68% over 2 years (disability progression reduced by 42% and MRI enhancing lesions by 92% compared to placebo) </p></td><td><p>INFUSION</p><p>Monthly IV infusions of 300mg </p><p>&nbsp;</p></td><td><p>Hypersensitivity reactions: anaphylaxis, urticarial, pruritis (4%-serious in 1% and can pre-treat with diphenhydramine/steroids), anxiety, fatigue, pharyngitis, sinus congestion, UTIs, vaginitis, peripheral edema and infusion-related symptoms (headache, flushing, erythema, nausea, fatigue and dizziness) </p><p>Rare hepatotoxicity </p><p>**Risk of PML</p></td><td><p><strong>JC virus serology and index q6months</strong></p><p>Immediate imaging to r/o PML if symptoms suggestive of PML (sub-acute worsening of visual, motor or cognitive changes) </p><p>&nbsp;</p><p>Pregnancy Category: C </p><p>&nbsp;</p><p>All patients must be enrolled in TOUCH program (REMS) </p></td></tr><tr><td><p><strong>Fingolimod (Gilenya) </strong></p><p>&nbsp;</p></td><td><p>Sphingosine-1-phosphate modulator which inhibits migration of T-cells from lymphoid tissue into peripheral circulation/CNS </p><p>Two phase 3 studies FREEDOMS and TRANSFORMS demonstrated that fingolimod was superior at reducing ARR (40-62%) and MRI activity in </p><p>RRMS compared to IFNb1a </p><p>&nbsp;</p></td><td><p>ORAL</p><p>0.5mg po qday </p><p>&nbsp;</p></td><td><p>First-dose bradycardia (patients need careful monitoring with initiation) </p><p>Herpes virus dissemination, macular edema (caution in diabetics) </p><p>HTN (with long term use); zoster infections; lymphopenia, PML (15 reported cases up to Sep 2015‚ÄîBUT 11 cases occurred in patients previously treated with Tysabri) </p><p>&nbsp;</p></td><td><p><strong>Initial dose: observation (EKG at baseline and 6hrs after first dose) and HR/BP q1hr  x 6hrs given it can cause bradyarrhythmia </strong></p><p><strong>*CBC and LFTs at baseline </strong></p><p><strong>*Ophtho eval/OCT at baseline and 3 months after start of treatment (or regularly if h/o uveitis or DM) </strong></p><p><strong>*Ensure previous </strong></p><p><strong>exposure to VZV or VZV serology and vaccinate if necessary </strong></p><p><strong>*Consider PFTs if the patient is a smoker </strong></p><p>Drug interactions: Class 1a/III antiarrhythmics, -azole antifungals, QTc prolonging agents </p><p>Pregnancy Category: C</p><p>REMS program </p></td></tr><tr><td><p><strong>Rituximab (Rituxan) </strong></p><p>&nbsp;</p></td><td><p>Binds to B-lymphoctye CD20 surface antigens inducing apoptosis </p><p>&nbsp;</p></td><td><p>INFUSION</p><p>375mg/m2 BSA (max 1 g) once and in 2 weeks, then ~q6 months</p><p> (check CD20 panel at ~5mnths to see if &lt;1 to decide if f/u dosing should be increased from induction dose) </p></td><td><p>Infusion reactions, lymphopenia, infection, Steven‚Äôs Johnson/TENs, hepatitis, nephrotoxicity, cardiotoxicity, pulmonary toxicity, PML </p><p>&nbsp;</p></td><td><p><strong>HBsAg, anti HBV, serum QuantiFERON gold and CD20 monitor panel at baseline, CBC q2-4mnths, EKG during infusion and immediate post-infusion if h/o arrhythmias or angina </strong></p><p>*Can pre-medicate with Diphenhydramine, APAP and methylpred IV</p><p><strong>Live-attenuated or live IZs 6 weeks before and not during treatment (less robust immune response)</strong></p><p>Pregnancy Category C </p></td></tr><tr><td><p><strong>Ocrelizumab </strong></p><p>&nbsp;</p></td><td><p>Recombinant human anti-CD20 </p><p>monoclonal antibody (binds to a different but overlapping CD20 isotope than Ritux) </p><p>&nbsp;</p><p>Phase 3 subgroup analysis showed </p><p>that ocrelizumab has efficacy in PPMS patients with and without enhancing lesions at baseline</p></td><td><p>INFUSION</p><p>Initiation: 300mg IV x2 doses separated by 2 weeks. </p><p>Maintenance: 600mg IV q6 mos</p></td><td><p>Most common: URIs and infusion reactions (pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, and tachycardia) ‚Äì can occur up to 24 hours after infusion</p><p>&nbsp;</p><p>Most serious: infusion reaction, skin/ Steven‚Äôs Johnson/TENs, PML, Hep B reactivation, HSV reactivation</p></td><td><p><strong>HBsAg, anti HBV, serum QuantiFERON gold and CD20 monitor panel at baseline, CBC q2-4mnths, EKG during infusion and immediate post-infusion if h/o arrhythmias or angina </strong></p><p>*Can pre-medicate with diphenhydramine, APAP and methylpred IV</p><p><strong>Live-attenuated and live IZs 6 weeks before and not during treatment</strong></p><p>Pregnancy Category C</p></td></tr></tbody></table></div><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"optic-neuritis\">Optic Neuritis</h1><p>&nbsp;</p><h3 id=\"epidemiology-2\"><strong>Epidemiology:</strong></h3><p>Age </p><ul><li>teens to 30s<ul><li>More likely to be bilateral in kids &lt; 10 yo</li></ul></li></ul><p>&nbsp;</p><h3 id=\"clinical-presentation-3\"><strong>Clinical Presentation:</strong></h3><ul><li>Progresses over days to 2 weeks</li><li>90% with pain (usually with eye movements due to stretching of the sheath)</li><li>Red desaturation (difficulty with night vision)<ul><li>Really all colors, but red especially</li></ul></li><li>RAPD (non specific for ON)</li><li>Optic disc edema - loss of margins over the superior and inferior parts of the disc (one of the first signs).  Optic disc hyperemia</li><li>2/3 are RETRObulbar, and might look normal</li><li>Central scotoma usually (although can be anything)</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>Differential:</strong></p><ul><li>Autoimmune - ADEM, MS, NMO, MOG, Sjogren‚Äôs, Sarcoidosis, SLE, APLA</li><li>Idiopathic</li><li>Other causes / mimics<ul><li>Optic glioma (NF1)</li><li>Retinal ischemia</li><li>Increased ICP (papilledema)</li><li>B12 deficiency</li><li>Infectious - TB, Lyme, syphilis, cat-scratch disease (Bartonella), WNV/HIV/VZV</li><li>Mitochondrial</li></ul></li></ul><p>&nbsp;</p><h3 id=\"evaluation-5\"><strong>Evaluation:</strong></h3><ul><li>Get orbital MRI WWO if trying to evaluate ON (thin slices, T1 fat desat signals with gad)</li><li><strong>95% sensitive for ON, but not 100% (still a clinical diagnosis)</strong><ul><li>Look at coronal slices with T1+POST for enhancement</li><li>Look at STIR - normally, should see nerve as dark with bright signal surrounding it</li><li>MRI Brain will miss <strong>ON 70% of the time (only 30% sensitive)</strong>, due to a different protocol from the Orbits protocol</li><li>MRI Brain WWO may assist in determining if part of a broader demyelinating syndrome</li><li>Serum anti-NMO and anti-MOG, LP with basic studies and OCBs</li></ul></li><li>R/o mimics if appropriate, or with risk factors for this (consider ANA, B12/MMA, Lyme, APLA, RPR, HIV, etc)</li></ul><p>&nbsp;</p><h3 id=\"treatment-5\"><strong>Treatment:</strong></h3><ul><li>High dose steroids (IV methypred 30/kg max 1 g) x 3 days, followed by 11 days oral pred (1mg/kg/day), then short oral pred taper. No oral steroids if related to MS.</li><li>Although this is the protocol used in the Optic Neuritis Treatment Trial, no good data for or against a steroid taper is present. If NMO or MOG is strongly suspected, consider continuing daily prednisone until antibody result is known. <ul><li>In ONTT, accelerated visual recovery (especially visual field defects) BUT did not improve visual outcomes at 6 months to 1 year (slightly better visual fields, contrast / color sensitivity, but similar visual acuity)</li><li>PLEX or IVIG if poor response within 7 days of initial steroids</li><li>IVIG doesn't have notable effect on long-term visual function</li><li>PLEX appears to have notable improvements in visual recovery when added to IV steroids for refractory ON or AON related to NMO</li></ul></li></ul><p>&nbsp;</p><h3 id=\"prognosis-4\"><strong>Prognosis:</strong></h3><ul><li>Visual recovery</li><li>&gt;80% of children had full visual recovery, some with recovery within 2-3 weeks</li><li>IF NOT RECOVERING within a couple weeks, have higher suspicion for NMO, sarcoidosis, or one of the non-demyelinating causes</li><li>Worse prognostic signs (also consider alternative causes):<ul><li>Clinical worsening after 2 weeks, NMO, recurrent optic neuritis, less than 20/50 vision at 4 weeks</li><li>Risk of MS</li><li>36% risk of progressing to MS within 2 years</li><li>Less of a risk to go to MS if &lt; 10 yo or &gt;40 yo</li><li>More of a risk if bilateral, or OCBs present</li><li>Less of a risk if normal MRI at presentation, or if &lt;10 yo</li><li>Risk of relapse of ON ‚Äì 35%</li></ul></li></ul><p>&nbsp;</p><p><strong>References:</strong></p><p>Voss E, Raab P, Trebst C, Stangel M. Clinical approach to optic neuritis: Pitfalls, red flags, and differential diagnosis. Ther Adv Neurol Disord. 2011; 4(2): 123-34. </p><p>Bennett JL, Nickerson M, Costello F, <em>et al.</em> Re-evaluating the treatment of acute optic neuritis. 2015;:799‚Äì808. doi:10.1136/jnnp-2014-308185</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"neuromyelitis-optica-spectrum-disorder-nmosd\">Neuromyelitis Optica Spectrum Disorder (NMOSD)</h1><p><strong>Diagnosis: </strong>NMOSD (International Consensus Criteria)</p><ul><li>Diagnostic Criteria for NMOSD <strong>with </strong>AQP4-IgG<ul><li>At least 1 core clinical characteristic</li><li>Positive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended)</li><li>Exclusion of alternative diagnoses</li></ul></li><li>Diagnostic Criteria for NMOSD <strong>without</strong> AQP4-IgG or unknown status<ul><li>At least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:<ul><li>At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome</li><li>Dissemination in space (2 or more core clinical characteristics)</li><li>Fulfillment of additional MRI requirements (for each core clinical characteristic)</li><li>Negative test for AQP4-IgG using best available detection method, or testing unavailable</li><li><strong>Exclusion of alternative diagnoses (especially important if Ab negative)</strong></li></ul></li></ul></li></ul><p>&nbsp;</p><ul><li>Core Clinical Characteristics<ul><li>Optic neuritis (usually chiasmal or deeper)</li><li>Acute myelitis</li><li>Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting</li><li>Acute brainstem syndrome</li><li>Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic demyelinating MRI lesions</li><li>Symptomatic cerebral syndrome with NMOSD-typical brain lesions</li></ul></li><li>Additional MRI requirements for NMOSD <strong>without </strong>AQP4 IgG<ul><li>Acute optic neuritis: requires brain MRI showing (a) normal findings or only nonspecific white matter lesions, OR (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium-enhancing lesion extending over 1/2 optic nerve length or involving optic chiasm</li><li>Acute myelitis: requires associated intramedullary MRI lesion extending over 3 or more contiguous segments (LETM) OR 3 or more contiguous segments of focal spinal cord atrophy in patients with history compatible with acute myelitis</li><li>Area postrema syndrome: requires associated dorsal medulla/area postrema lesions</li><li>Acute brainstem syndrome: requires associated peri-ependymal brainstem lesions</li></ul></li></ul><p>&nbsp;</p><h3 id=\"evaluation-6\"><strong>Evaluation: </strong></h3><ul><li>MRI Brain and Orbits with and without contrast (with fat saturation for better evaluation of optic nerves) ‚Äì may see optic nerve enhancement, may see symmetric hypothalamic or thalamic, periaqueductal grey, or large hemispheric WM lesions (no Dawson‚Äôs fingers)</li><li>MRI C/T/L spine with and without contrast (Can sometimes do C/T spine on small patients if you can visualize conus medullaris ‚Äì check with rads)</li><li>Serum NMO is 78 % sensitive and 100% specific but may not be positive on initial testing in up to 12% of patients (re-test in 6 months if high suspicion) ‚Äì <em>test on un-treated serum/CSF if possible</em></li><li>Serum MOG ab ‚Äì some antibody negative NMOSD may be anti-MOG disease</li><li>LP with basic studies, OCBs (5-10%)</li><li>DDX: MS, ADEM, MOG (see lists in other sections on ADEM, MS, Encephalitis, etc)</li></ul><p>&nbsp;</p><h3 id=\"treatment-6\"><strong>Treatment:</strong></h3><ul><li>Acute:<ul><li>IV methylprednisolone 30mg/kg/day (max 1g) q24 hours for 3-5 days</li><li>GI prophylaxis</li><li>Low threshold for PLEX and/or eculizumab if transverse myelitis, or refractory to steroids</li><li>IVIG not typically used in this setting unless refractory to steroids + PLEX</li></ul></li><li>Long term tx ‚Äì immunosuppression typically required.<ul><li>Rituximab most often, but recently ineblizumab (anti-CD19) in adults may be more effective. Also, can use azathioprine, mycophenolate, methotrexate, eculizumab, or satralizumab/tocilizumab (IL6 inhibitor)</li><li>No strict consensus on best long-term treatment</li><li>Usually continued for several years if NMO Ab+ because of high risk of relapse</li></ul></li></ul><h3 id=\"prognosis-5\"><strong>Prognosis:</strong></h3><ul><li>Stepwise deterioration due to accumulating symptoms</li><li>Relapses occur in over 90% of patients</li><li>Visual disability higher with NMO than with idiopathic or MS-related ON</li><li>High change of other systemic autoantibody diseases ‚Äì SLE, Sjogren‚Äôs, etc</li><li>Predictors of worse prognosis‚Äì number of relapses within the first two years, severity of first attack, older age at onset, association with other auto-immune diseases, +NMO antibody</li></ul><p>&nbsp;</p><p><strong>References: </strong></p><p>Jarius S, Wildemann B, Paul F. Neuromyelitis optica: Clinical features, immunopathogenesis and treatment. <em>Clin Exp Immunol</em> Published Online First: 2014. doi:10.1111/cei.12271</p><p>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"mog-antibody-disease-mogad\">MOG Antibody Disease (MOGAD)</h1><p>&nbsp;</p><h3 id=\"clinical-presentation-4\"><strong>Clinical Presentation:</strong></h3><ul><li>Optic neuritis (54%, bilateral in 32%)</li><li>Myelitis (18-23%)</li><li>ON + spinal cord involvement (especially thoracolumbar)</li><li>More in male teens or adults</li><li>ADEM-like in kids (20%), leukodystrophy-like presentations (antibody might be generated secondary to neurodegeneration)</li><li>Brainstem encephalitis (8-14%)</li><li>Seizures may occur in kids (more often than in NMO)</li><li>Can present as FLAMES: FLAIR hyperintense lesions in anti-MOG encephalitis with seizures</li></ul><p>&nbsp;</p><p><strong> Diagnostic Criteria (per consensus paper 2023, must meet all 3 criteria):</strong></p><ul><li>Core clinical demyelinating event: Optic neuritis, myelitis, ADEM, cerebral monofocal or polyfocal deficits, brainstem or cerebellar deficits, cerebral cortical encephalitis (often with seizures)</li><li>Positive serum MOG IgG<ul><li>If clearly positive (titer &gt;1:100), no additional supporting features needed</li><li>If low positive, titer not available, or serum negative but CSF positive, also need a negative AQP4-IgG AND ‚â•1 additional supporting feature<ul><li>Supporting features: <strong>optic neuritis</strong> (bilateral, longitudinal, perineural sheath enhancement, optic disc edema), <strong>myelitis</strong> (longitudinally extensive, ‚ÄúH-sign‚Äù or central cord lesion, conus lesion) <strong>+/- brain, brainstem or cerebral syndrome</strong> (multiple ill-defined T2 hyperintense lesions in white matter, deep grey matter involvement, ill-defined T2-hyperintensity involving pons, middle cerebellar peduncle, or medulla, cortical lesion with or without lesional and overlying meningeal enhancement</li></ul></li></ul></li><li>Exclusion of better diagnoses including multiple sclerosis</li></ul><p>&nbsp;</p><h3 id=\"evaluation-7\"><strong>Evaluation:</strong></h3><ul><li>Serum - Anti-MOG, anti NMO, peds autoimmune CNS panel</li><li>LP<ul><li>Majority have a pleocytosis, may have neutrophilic</li><li>OCBs - uncommon (11%)</li><li>Consider Quest CSF Anti-MOG if high suspicion but serum testing negative</li></ul></li><li>MRI findings<ul><li>May be very similar to NMOSD in appearance<ul><li>High prevalence of LETM</li></ul></li><li>Less striking contrast enhancement compared to ADEM?</li><li>Can see leptomeningeal enhancement/thickening</li><li>Supratentorial MRI lesions (35%)</li><li>ON (including bilateral ON) <ul><li>Even if only clinically unilateral, often subclinical atrophy of the other nerve</li><li>Brainstem lesions (pons / adjacent to 4th ventricles), bilateral - 30% of patients</li><li>\"Fluffy\" appearance</li></ul></li><li>Myelitis<ul><li>2/3 with LETM</li><li>More lower cord and conus involvement (thoracolumbar)</li><li>Tend to have central/lateral involvement</li></ul></li></ul></li></ul><p>&nbsp;</p><h3 id=\"treatment-7\"><strong>Treatment:</strong></h3><ul><li>Acute<ul><li>IV methylprednisolone x 5 days, and oral pred taper over 4 weeks</li><li>PLEX if severe presentation</li><li>Consider tocilizumab also if severe</li></ul></li><li>Long term (consider if recurrent relapses, continue for ~12-24 months)<ul><li>If relapse while weaning steroids, consider just upping the steroids again and slowing wean</li><li>If relapse 30+ days after steroids are weaned:<ul><li>IVIG - regular dosing (2g/kg over 3 days to start, then 1g/kg every 4 weeks afterwards) ‚Äì may be most effective strategy for recurrent anti-MOG</li><li>Rituximab - 30-50% response rate (much lower than other diseases)</li><li>Tocilizumab (recurrent disease refractory to IVIg)</li></ul></li></ul></li></ul><p>&nbsp;</p><h3 id=\"prognosis-6\"><strong>Prognosis:</strong></h3><ul><li>Rare to have co-existing autoimmune diseases</li><li>Multi-phasic course in 80%, annualized relapse rate of 0.9</li><li>Higher risk if concurrent OCBs, or persistent anti-MOG over 3-6 months</li><li>1/3 of patients with ON and 1/2 of patients with myelitis made full recoveries</li></ul><p>&nbsp;</p><p><strong>Reference: </strong></p><p>Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-282</p><p>Jarius S, Ruprecht K, Kleiter I, <em>et al.</em> MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <em>J Neuroinflammation</em> 2016;13:1‚Äì45.</p><p>Ramanathan S, Mohammad S, Tantsis E, <em>et al.</em> Clinical course , therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. 2018;:127‚Äì37.</p><p>Ringelstein M, et al; Neuromyelitis Optica Study Group (NEMOS). Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100.</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"facial-nerve-cranial-nerve-vii-palsy\">Facial nerve (cranial nerve VII) palsy</h1><h3 id=\"clinical-presentation-5\"><strong>Clinical Presentation:</strong></h3><ul><li>Upper and lower facial weakness</li><li>Hyperacusis</li><li>Taste change</li><li>\"increased\" tearing ‚Äì actually decreased production, but just not clearing tears well</li><li>Difficulty closing eye fully, leading to asymmetric blink</li><li>Pain behind the ear (small sensory component)</li></ul><p>&nbsp;</p><p><strong>Differential / Causes:</strong></p><ul><li>Idiopathic (Bell‚Äôs Palsy)</li><li>HSV/VZV</li><li>Lyme (most common cause in locations with endemic Lyme)</li><li>Otomastoiditis</li><li>Trauma, post-surgical</li><li>Rare: Schwannoma or other compressive tumor, neuropsychiatric lupus, leukemia</li></ul><p>&nbsp;</p><p><strong>Treatment (if within 3 days of presentation):</strong></p><ul><li>1mg/kg/day (max 60mg/day) x 5 days +/- 5 day taper<ul><li>1 mg/kg/day as effective as 2 mg/kg/day, less side effects (Arican 2017)</li><li>However, recent double-blind placebo-controlled study showed no statistically significant difference in recovery: 49% of pred group vs 57% in placebo group at 1 month, and 99% in pred group and 93% in placebo group at 6 months<ul><li>Consider risk-benefit discussion with family</li></ul></li></ul></li><li>Antivirals (could consider‚Ä¶some argue for this in adults)</li><li>Valacyclovir 20 mg/kg (max 1 g) q8h x 5 days</li><li>Doxycycline - if concerned for Lyme disease or exposure</li><li>Eye care ‚Äì ensure artificial tears and eye lubricant at night to prevent secondary damage</li><li>Consider outpatient PT/OT to help prevent synkinesis</li><li>Treatment of any secondary causes (trauma, otomastoiditis, SLE, etc)</li></ul><p>&nbsp;</p><h3 id=\"prognosis-7\"><strong>Prognosis:</strong></h3><ul><li>May worsen for a few weeks, then plateau/improve around week 3. Recovery over months to 1 year</li><li>&gt;90% with complete recovery by 6 months</li><li>Consider referral for nerve grafting if not having good progress after 6 weeks. Consider evaluation for other causes of facial nerve paralysis (imaging, etc)</li><li>5% may develop facial synkinesis (‚Äúcrocodile tears‚Äù, or eye blink whenever smiling)</li></ul><p>&nbsp;</p><p><strong>References: </strong></p><p>Arican P, Dundar NO, Gencpinar P, <em>et al.</em> Efficacy of Low-Dose Corticosteroid Therapy Versus High-Dose Corticosteroid Therapy in Bell‚Äôs Palsy in Children. <em>J Child Neurol</em> 2017;<strong>32</strong>:72‚Äì5.</p><p>&nbsp;</p><p>Babl FE, et al; Paediatric Research in Emergency Departments International Collaborative (PREDICT). Efficacy of Prednisolone for Bell Palsy in Children: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Neurology. 2022 Aug 25:10 </p><p>&nbsp;</p><p>Ciorba A, Corazzi V, Conz V, <em>et al.</em> Facial nerve paralysis in Children. World Journal of Clinical Cases. 2015;<strong>3</strong>:973‚Äì80.</p><p>&nbsp;</p><p>&nbsp;</p><h1 id=\"post-viral-cerebellar-ataxia-cerebellitis\">Post-viral cerebellar ataxia / cerebellitis</h1><p>&nbsp;</p><h3 id=\"epidemiology-3\"><strong>Epidemiology:</strong></h3><ul><li>Before VZV vaccine, 50% were VZV-related</li><li>Can be post-vaccination or any number of post-viral causes; several days to several weeks after</li><li>Age generally &lt; 6 yo, but can be seen into adolescence</li></ul><p>&nbsp;</p><h3 id=\"clinical-presentation-6\"><strong>Clinical Presentation:</strong></h3><ul><li>Cerebellar ataxia: In kids, first sign may be refusal to walk. May also have gait/truncal ataxia, dysmetria, intention tremor, nystagmus, speech changes, vomiting, or headache</li><li>Cerebellitis: May see encephalopathy, mutism, persistent headache (hydrocephalus), or focal signs (brainstem compression), fever, meningismus</li></ul><p>&nbsp;</p><h3 id=\"evaluation-8\"><strong>Evaluation:</strong></h3><ul><li>R/o other causes of acute ataxia if indicated by history (ingestion, metabolic work-up if recurrent, stroke, mass, Miller-Fisher, opsoclonus-myoclonus, etc) ‚Äì LP, MRI, Utox/ethanol, etc</li><li>If &lt;3 days from onset, and &lt;3 yo, neuroimaging yield is &lt;1%</li><li>If &gt;3 days of sx, older child, or with focal signs, encephalopathy, persistent headache: neuroimaging to rule out cerebellitis or other cause of ataxia</li><li>LP, if performed, shows a predominantly lymphocytic pleocytosis in ~50%. OCBs present in 10-17%</li></ul><p>&nbsp;</p><h3 id=\"treatment-8\"><strong>Treatment:</strong></h3><ul><li>Cerebellar ataxia: supportive care, PT</li><li>Cerebellitis: <ul><li>Controversy on steroids, but most case series have used 10-14 days of steroids (initially dexamethasone, transition to pred taper after several days) ‚Äì may decrease swelling, surgical need, long-term morbidity</li><li>If hydrocephalus, may need neurosurgical management</li><li>Supportive care, PT/OT/SLP/Rehab</li></ul></li></ul><p>&nbsp;</p><h3 id=\"prognosis-8\"><strong>Prognosis:</strong></h3><ul><li>Cerebellar ataxia improves over 2-3 weeks to months, with only 10% with mild residual deficits</li><li>Cerebellitis recovery takes months to a year, with 14% with residual motor/speech deficits at 1 year. Higher risk of mortality from consequences of swelling. MRI findings do not accurately predict level of permanent injury.</li></ul><p>&nbsp;</p><p><strong>References: </strong></p><p>Desai J, Mitchell WG. Acute Cerebellar Ataxia , Acute Cerebellitis , and Opsoclonus-Myoclonus Syndrome. 2012;<strong>27</strong>:1482‚Äì8. </p><p>&nbsp;</p><p>Rudloe T, Prabhu SP, Gorman MP, <em>et al.</em> The Yield of Neuroimaging in Children Presenting to the Emergency Department with Acute Ataxia in the Post-Varicella Vaccine Era. <em>J Child Neurol</em> 2015;<strong>30</strong>:1333‚Äì9.</p>",
  "imageCount": 0,
  "chunkCount": 40
}